Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apantamide and Docetaxel in High Tumor Burden mHSPC
NCT05713578Phase 1Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: radiographic progression free survival rate at 3 years. Started Mar 2023; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05713578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713578.